<DOC>
	<DOCNO>NCT00884286</DOCNO>
	<brief_summary>This multicenter study assess anti-tumour activity , investigate safety profile obtain additional pharmacokinetic information Aplidin® give 1-hour weekly IV infusion patient aggressive non-Hodgkin 's Lymphoma .</brief_summary>
	<brief_title>Multicenter Trial Treat Patients With Relapsed/Refractory Aggressive Non Hodgkin Lymphoma</brief_title>
	<detailed_description>A Phase II Multicenter , Open-Label , Clinical And Pharmacokinetic Study Of Aplidin® As A 1-Hour Weekly IV Infusion , In Patients With Relapsed Or Refractory aggressive non-Hodgkin 's Lymphoma . Primary • To assess anti-tumour activity Aplidin® give 1-hour weekly IV infusion , patient aggressive non-Hodgkin 's Lymphoma , relapse refractory prior therapy . Secondary - To investigate safety profile Aplidin® give 1-hour weekly IV infusion patient population . - To obtain additional pharmacokinetic information Aplidin® give 1-hour weekly IV infusion patient aggressive non-Hodgkin 's Lymphoma .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Aggression</mesh_term>
	<criteria>Written inform consent Histologically confirm aggressive lymphoma , Patient require treatment NHL relapse Measurable disease Recovery nonhematological toxicity derive previous treatment . The presence alopecia NCICTC grade &lt; 2 symptomatic peripheral neuropathy allow . Age &gt; 18 year . Performance status ( ECOG ) &lt; 2 Adequate renal , hepatic , bone marrow function ( assessed &lt; 14 day inclusion study ) Left ventricular ejection fraction within normal limit . Prior therapy Aplidin® . Concomitant therapy antilymphoproliferative agent Acute lymphoblastic leukemia . CNS lymphoma . HIVassociated lymphoma . Prior gene therapy viral vector . More three previous line systemic biological agent chemotherapy . Washout period since end precedent therapy le : 6 week nitrosourea high dose chemotherapy 3 week chemotherapies biological agent 4 week radiation radionuclide therapy ( 6 week case prior extensive external beam radiation ( 25 % bone marrow distribution ) . 4 week major prior surgery 30 day investigational product 4 week immunosuppressive therapy allogeneic hematopoietic stem cell transplantation . Pregnant lactating woman . Men woman reproductive potential use effective contraceptive method History another neoplastic disease . Exceptions : Nonmelanoma skin cancer , cCarcinoma situ site , cancer curatively treat evidence disease least 10 year . Known cerebral leptomeningeal involvement . Other relevant disease adverse clinical condition Treatment investigational product 30 day period inclusion study . Known hypersensitivity Aplidin® , mannitol , cremophor EL , ethanol Limitation patient 's ability comply treatment followup protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Aplidin</keyword>
	<keyword>Aggressive Non Hodgkin Lymphoma</keyword>
	<keyword>Leukemia-Lymphoma , Adult T-Cell B-cell</keyword>
</DOC>